Resources

Quality

FDA Registration

Aquila Bioscience have been successfully registered as a foreign manufacturing facility with FDA under Owner/ Operator Number 10074735

The ABD Wipe product is registered with FDA under device listing D405606.

Aquila Bioscience are now permitted to market and sell the ABD Device in the US market.

CE Mark

Path to CE mark is underway and is expected to be completed in 2021

Accreditation

NeoVirTech – French Labratory of expertise has proven the efficiency of the ABD Device in its ability to capture and remove up to 99.99% of SARS CoV-2 from the human skin.

Aquila Bioscience in the News

Irish Innovation in Wipes and Masks Could Help Battle Emerging Coronavirus Crisis

Aquila Bioscience on Newstalk

‘Living Velcro’ used to trap viruses

Innovation is key in battle against Covid-19

An emerging Irish technology may be key to containing the Wuhan coronavirus

First consignment of Galway-manufactured wipe that can help fight Covid-19 delivered to Defence Forces

Higher Education Research Activity in response to COVID-19

ABD Device supports emergency response teams

Reports

28th October 2020

Irish Company Develop Technology Proven to Remove 99.99% of Coronavirus from Human Skin

Aquila Bioscience has successfully proven that its breakthrough Pathogen Capturing Technology safely removes 99.99% of SARS-CoV-2 from human skin. This is the first time a nature inspired, safe and non-toxic technology that is free from all harmful chemicals, has been proven to remove COVID-19 with such efficiency. The results show that this novel technology is equally if not more effective as the highest performing chemical-based methods currently on the market but without any of the environmental or health problems.

8th June 2020

Aquila Bioscience is selected for EIC Accelerator Funding

Aquila Bioscience has developed revolutionary decontamination technology that helps protect people from dangerous pathogens and other viral infections like coronavirus. We are delighted to receive funding from EIC which allows us to substantially scale up production and deliver this technology more quickly to frontline and other workers in Ireland and across the globe. This technology will make it safer for people to return to work and help get Ireland’s economy moving again.

29th May 2020

Aquila Bioscience Registered with FDA